The short version of analytical characterisation fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2025-11-29. Anything still debated is marked as such rather than presented as settled.
Melanotan II holds no marketing authorisation from the Food and Drug Administration, the European Medicines Agency, the UK Medicines and Healthcare products Regulatory Agency or Australia's Therapeutic Goods Administration. Products sold under that name are treated as unapproved new drugs, and their sale or import is prohibited in several jurisdictions. Other countries classify the peptide as a prescription-only medicine or place it among controlled substances, so the legal position changes with the destination market. No pharmacopoeial monograph supplies an official specification, because the material is not a licensed pharmaceutical. Consequently, products offered online are not manufactured to a shared public standard.
The peer-reviewed record is dominated by small early-phase studies, case reports and pharmacovigilance summaries rather than large randomised trials. Papers typically examine tanning response, receptor selectivity or patterns of reported adverse events. Many note that participants obtained the peptide outside a clinical setting, which limits verification of composition and administered amount. Reported events vary widely, and causality is frequently unclear because the identity and purity of self-sourced material are unknown. Open questions include whether repeated melanocortin receptor stimulation produces cumulative effects, and how often label claims match actual content.
Identification in laboratories relies on reversed-phase liquid chromatography coupled with tandem mass spectrometry, with product-ion spectra compared against a certified reference standard. High-resolution mass spectrometry supplies accurate mass confirmation, and peptide mapping after enzymatic digestion separates melanotan II from closely related analogues. Quantitation of seized material is complicated by unknown counter-ions and residual trifluoroacetate left from purification. Immunoassays raised against alpha-melanocyte-stimulating hormone can cross-react, so chromatographic confirmation is normally required. Urinary detection windows are short, and reported limits of detection differ substantially between laboratories.
Melanotan II is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its structure substitutes a lactam bridge between side chains to increase stability relative to the native hormone. The compound is also known by the shorthand MT-II and by several non-proprietary synonyms used in research catalogues. It is not an approved therapeutic product in any major jurisdiction; material sold under this name is typically offered as a laboratory reagent rather than as a medicine.
Activity is attributed to agonism at melanocortin receptors, particularly MC1R and MC4R. Activation of MC1R on melanocytes increases melanin synthesis, which underlies the reported tanning effect. MC4R engagement in the central nervous system is linked to appetite suppression and to effects on sexual arousal reported in early clinical studies. Those studies were small and were not designed to establish efficacy or long-term safety. Receptor selectivity among the melanocortin subtypes is not absolute, which complicates attribution of any effect to a single pathway.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Unapproved in the US, EU and Australia | Sale and import restricted; no licensed product |
| Typical test matrices | Urine, serum, seized powder | Urinary detection window is short |
| Primary identification method | LC-MS/MS against a reference standard | High-resolution mass used for confirmation |
| Data sources in the literature | Small trials, case reports, pharmacovigilance | No registrational trial dataset exists |
| Common marketing names | Melanotan 2, MT-II, MT-2 | Label content may not match declared peptide |
Scientific discussion of Melanotan-2 spans pharmacology, dermatology, and public-health literature. Laboratory studies examine its receptor binding and cellular effects, while clinical reports describe outcomes observed after unregulated use. These two bodies of work differ in rigour and intent. Peer-reviewed trials of the compound as a medicine are limited, so much of the available information comes from case reports and surveillance data. Authors frequently note the gap between experimental findings and real-world use.
Reported observations after unregulated use include shifts in skin pigmentation and, in some accounts, unintended changes to moles and other lesions. Whether these outcomes are causally linked to the compound, and how often they occur, remain open questions because controlled data are scarce. The absence of standardised dosing and verified product purity complicates interpretation. Researchers have called for better surveillance and analytical characterisation of samples obtained outside regulated channels. Conclusions drawn from anecdotal evidence should be treated as provisional.
Outside regulated medicine, melanotan II circulates through online vendors as a research chemical, often marketed for tanning. Products sold this way vary widely in purity, concentration, and labeling accuracy, and independent testing has documented discrepancies. Published reports describe both pigment effects and adverse reactions, including nausea, flushing, and darkening of existing moles. Long-term safety data are sparse, and no large controlled trial has established a risk profile. Questions about cumulative effects on melanocytes remain unresolved in the literature.
Melanotan II is a synthetic peptide analog modeled on alpha-melanocyte-stimulating hormone, a naturally occurring signaling peptide involved in pigmentation. Its structure is a cyclic heptapeptide containing two non-natural substitutions, norleucine at position four and D-phenylalanine at position seven. These modifications resist enzymatic breakdown and extend the molecule's activity relative to the native hormone. The compound binds melanocortin receptors and is studied mainly as a pharmacological tool rather than a therapeutic product. It has never received approval as a medicine in any major jurisdiction.
The compound was developed in the late 1980s and 1990s by academic researchers investigating photoprotection. The rationale held that stimulating melanin production might reduce ultraviolet damage to skin and lower skin cancer risk. Early work examined receptor binding, pigment response, and short-term tolerability in small studies. That program did not produce an approved drug, and formal development stalled after early-phase trials. Whether induced pigmentation confers meaningful photoprotection remains an open question.
Regulatory treatment varies by jurisdiction and has changed over time. In several countries the peptide is handled as an unapproved prescription medicine, and import or sale for human use is restricted, while elsewhere it falls under poisons or controlled-substance schedules. Enforcement activity against online vendors has been reported in Australia, New Zealand, the United Kingdom and the United States. Scholarly writing discusses melanotan-2 chiefly as an experimental tool and as a case study in unregulated peptide supply, and its precise legal position in any given country should be checked against current national schedules.
Lyophilised melanotan-2 is comparatively robust when kept dry, cold and dark, and a desiccated powder stored at minus twenty degrees Celsius or below is generally expected to retain its chemical integrity for extended periods. In solution the peptide is far less stable, with degradation proceeding through oxidation of tryptophan and histidine residues, hydrolysis adjacent to the lactam bridge, and aggregation at higher concentrations. Repeated freeze-thaw cycling accelerates loss of the parent peak. Working aliquots are therefore prepared once, held cold, and used without letting the stock return to ambient temperature.
Peroxidases or peroxide reductases (EC number 1.11.1.x) are a large group of enzymes which play a role in various biological processes. They are named after the fact that they commonly break up peroxides, and should not be confused with other enzymes that produce peroxide, which are often oxidases.
This phenomenon further promotes heterogeneity and produces a gradient in the microenvironment that fosters the positive selection of a drug-resistant cell population, where cells sensitive to treatment decrease in population size . Plasticity in tumor cells has, additionally, been recognized as a byproduct of tumor heterogeneity and a major contributor to resistance. Tumor cells have the ability to gain stem-like traits in response to changes in their microenvironment, allowing for the survival of cell populations, which ultimately promotes resistance through selection. Tumor cell plasticity is a notable mechanism of acquired resistance. In order to assess the potential reversibility of plasticity in tumor cells, mathematical models informed by tumor heterogeneity and inter-cellular differences have been created. Cellular heterogeneity describes the recently studied phenomenon of genetically identical cells varying in phenotype, cellular response, and drug sensitivity. Cell-to-cell response variability has been attributed to random, stochastic biochemical processes that facilitate protein expression. These intracellular biochemical fluctuations create variation in genetically identical cells by producing unique proteomes and subsequently differing phenotypic responses to drugs even within the same environment.
Research has shown that a mutation of G—>C in the −6 position of the β-globin gene (β+45; human) disrupted the haematological and biosynthetic phenotype function. This was the first mutation found in the Kozak sequence and showed a 30% decrease in translational efficiency. It was found in a family from the Southeast Italy and they suffered from thalassaemia intermedia. Similar observations were made regarding mutations in the position −5 from the start codon, AUG. Cytosine in this position, as opposed to thymine, showed more efficient translation and increased expression of the platelet adhesion receptor, glycoprotein Ibα in humans. Mutations to the Kozak sequence can also have drastic effects upon human health; in particular, certain forms of congenital heart disease are caused by Kozak sequence mutations in the GATA4 gene's 5' untranslated region. The GATA4 gene is responsible for gene expression in a wide variety of tissues including the heart. When the guanosine at the -6 position in the Kozak sequence of GATA4 is mutated to a cytosine, a reduction in GATA4 protein levels results, which leads to a decrease in the expression of genes regulated by the GATA4 transcription factor and linked to the development of atrial septal defect. The ability of the Kozak sequence to optimize translation can result in novel initiation codons in the typically untranslated region of the 5′ (5′ UTR) end of the mRNA transcript. A G to A mutation was described by Bohlen et al.
Sources: en.wikipedia.org
== Function == The main purpose of chondronectin is to allow chondrocytes and collagen II substrates to bond together. When bound, if forms a complex structure called an extracellular scaffold, which helps support the surrounding cells because of bioactive molecule diversity, which allows for chondrocytes to be anchored, mechanical forces to be bared, and maintaining physiological homeostasis. In order for chondronectin to be able to assist in binding within this complex as efficiently as possible, they must interact with a cartilage proteoglycan monomer. If there is a inhibitor that prevents synthesis of endogenous proteoglycans, along with beta-xylosides, it fully prevents chondrocytes from attaching via chondronectins. When cartilage cells attach chondronectin help keep the cells positioned close to important collagen and proteoglycan materials within the extracellular matrix. This allows the cells to support the framework by maintaining surrounding cartilage components. Without attachment, chondrocytes become less effective at preserving the tissue around them. Chondronectin keeps the cartilage framework strong enough to handle daily joint pressure. It helps cartilage deal with the stress caused by regular movement and compression. Since joints face constant wear, cell bonds must stay stable to help prevent tissue damage. This protein plays a key role in keeping cartilage durable and properly supported. Studies indicate that weak adhesive interaction inside cartilage matrix can gradually reduce the integrity to cartilage.
== Part 1 == This 90-minute video shows how Metallica and their producer Bob Rock worked their way through making the Metallica album. It also includes the making of the video for "Enter Sandman" and also a listening party for invited fans to come and listen to the album in full. The video as well highlights tensions between Bob Rock and Metallica. The infamous exchange between Kirk Hammett and Bob Rock during the recording of "The Unforgiven" guitar solo is documented. This video also includes three of the music videos the band shot for that album:
=== Journal articles === Martin, Dianne L. (1993). "Casualties of the Criminal Justice System: Women and Justice Under the War on Drugs". Canadian Journal of Women & the Law. 6 (2): 305–327. Hall, Mary F. (June 1997). "The "War on Drugs": A Continuation of the War on the African American Family". Smith College Studies in Social Work. 67 (3): 609–621. doi:10.1080/00377319709517509. Enid Logan (1999). "The Wrong Race, Committing Crime, Doing Drugs, and Maladjusted for Motherhood: The Nation's Fury over "Crack Babies"". Social Justice. 26 (1): 115–138. JSTOR 29767115. Gorton, Joe; Boies, John L (March 1999). "Sentencing Guidelines and Racial Disparity across Time: Pennsylvania Prison Sentences in 1977, 1983, 1992, and 1993". Social Science Quarterly. 80 (1): 37–54. JM Wallace (May 1999). "The social ecology of addiction: race, risk, and resilience". Pediatrics. 103 (5 Pt. 2): 1122–1127. doi:10.1542/peds.103.S2.1122. PMID 10224199. S2CID 36314201. Graham Boyd (July–August 2001). "The Drug War is the New Jim Crow". NACLA Report on the Americas. 35 (1): 18. doi:10.1080/10714839.2001.11722573. S2CID 159998188. Deborah Small (Fall 2001). "The War on Drugs Is a War on Racial Justice". Social Research. 68 (3): 896–903. Kenneth B. Nunn (2002). "Race, Crime and the Pool of Surplus Criminality: Or Why the War on Drugs Was a War on Blacks". Gender, Race & Justice. 6 (6): 381. Gabriel Chin (2002). "Race, the War on Drugs and the Collateral Consequences of Criminal Conviction". Gender, Race & Justice (6): 253. doi:10.2139/ssrn.390109. SSRN 390109. Samuel R. Gross; Katherine Y.
Top-grain leather includes the outer layer of the hide, known as the grain, which features finer, more densely packed fibers, resulting in strength and durability. Depending on thickness, it may also contain some of the more fibrous under layer, known as the corium. Types of top-grain leather include: Full-grain leather contains the entire grain layer, without any removal of the surface. Rather than wearing out, it develops a patina during its useful lifetime. It is usually considered the highest quality leather. Furniture and footwear are often made from full-grain leather. Full-grain leather is typically finished with a soluble aniline dye. Russia leather is a form of full-grain leather. Corrected grain leather has the surface subjected to finishing treatments to create a more uniform appearance. This usually involves buffing or sanding away flaws in the grain, then dyeing and embossing the surface. Nubuck is top-grain leather that has been sanded or buffed on the grain side to give a slight nap of short protein fibers, producing a velvet-like surface. Split leather is created from the corium left once the top-grain has been separated from the hide, known as the drop split. In thicker hides, the drop split can be further split into a middle split and a flesh split. Bicast leather is split leather that is coated with a layer of polyurethane or vinyl with an embossed texture. This gives it the appearance of a grain. It is slightly stiffer than top-grain leather but has a more consistent texture.
Sources: en.wikipedia.org
Regulatory treatment varies by country. In the United States, the European Union and Australia it is an unapproved drug and its sale is restricted, while some other jurisdictions list it as prescription-only or controlled. The applicable rules depend on the country of import.
Reversed-phase LC-MS/MS is the usual approach for both identification and quantitation. High-resolution mass spectrometry and peptide mapping serve as confirmatory methods. Immunoassays are rarely used alone because of cross-reactivity.
Published testing of seized and purchased samples frequently reports discrepancies between declared and measured peptide content. Counter-ion content and residual solvents add further variation. Independent analysis is the only way to confirm composition.
No. No major regulatory agency has granted a marketing authorisation for melanotan II as a medicine. Products sold under this name are generally presented as laboratory reagents and are not subject to the batch-release testing applied to approved drugs.